509 related articles for article (PubMed ID: 25528771)
1. Targeting the facilitative glucose transporter GLUT1 inhibits the self-renewal and tumor-initiating capacity of cancer stem cells.
Shibuya K; Okada M; Suzuki S; Seino M; Seino S; Takeda H; Kitanaka C
Oncotarget; 2015 Jan; 6(2):651-61. PubMed ID: 25528771
[TBL] [Abstract][Full Text] [Related]
2. A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo.
Liu Y; Cao Y; Zhang W; Bergmeier S; Qian Y; Akbar H; Colvin R; Ding J; Tong L; Wu S; Hines J; Chen X
Mol Cancer Ther; 2012 Aug; 11(8):1672-82. PubMed ID: 22689530
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Glut1 by WZB117 sensitizes radioresistant breast cancer cells to irradiation.
Zhao F; Ming J; Zhou Y; Fan L
Cancer Chemother Pharmacol; 2016 May; 77(5):963-72. PubMed ID: 27011212
[TBL] [Abstract][Full Text] [Related]
4. Targeting the K-Ras--JNK axis eliminates cancer stem-like cells and prevents pancreatic tumor formation.
Okada M; Shibuya K; Sato A; Seino S; Suzuki S; Seino M; Kitanaka C
Oncotarget; 2014 Jul; 5(13):5100-12. PubMed ID: 24947996
[TBL] [Abstract][Full Text] [Related]
5. Influence of glucose transporter 1 activity inhibition on neuroblastoma in vitro.
Peng Y; Xing SN; Tang HY; Wang CD; Yi FP; Liu GL; Wu XM
Gene; 2019 Mar; 689():11-17. PubMed ID: 30553996
[TBL] [Abstract][Full Text] [Related]
6. Transforming growth factor-beta1 promotes the migration and invasion of sphere-forming stem-like cell subpopulations in esophageal cancer.
Yue D; Zhang Z; Li J; Chen X; Ping Y; Liu S; Shi X; Li L; Wang L; Huang L; Zhang B; Sun Y; Zhang Y
Exp Cell Res; 2015 Aug; 336(1):141-9. PubMed ID: 26096658
[TBL] [Abstract][Full Text] [Related]
7. WZB117 (2-Fluoro-6-(m-hydroxybenzoyloxy) Phenyl m-Hydroxybenzoate) Inhibits GLUT1-mediated Sugar Transport by Binding Reversibly at the Exofacial Sugar Binding Site.
Ojelabi OA; Lloyd KP; Simon AH; De Zutter JK; Carruthers A
J Biol Chem; 2016 Dec; 291(52):26762-26772. PubMed ID: 27836974
[TBL] [Abstract][Full Text] [Related]
8. Cancer stem cells and self-renewal.
O'Brien CA; Kreso A; Jamieson CH
Clin Cancer Res; 2010 Jun; 16(12):3113-20. PubMed ID: 20530701
[TBL] [Abstract][Full Text] [Related]
9. Side population is not necessary or sufficient for a cancer stem cell phenotype in glioblastoma multiforme.
Broadley KW; Hunn MK; Farrand KJ; Price KM; Grasso C; Miller RJ; Hermans IF; McConnell MJ
Stem Cells; 2011 Mar; 29(3):452-61. PubMed ID: 21425408
[TBL] [Abstract][Full Text] [Related]
10. RNAi-mediated silencing of Myc transcription inhibits stem-like cell maintenance and tumorigenicity in prostate cancer.
Civenni G; Malek A; Albino D; Garcia-Escudero R; Napoli S; Di Marco S; Pinton S; Sarti M; Carbone GM; Catapano CV
Cancer Res; 2013 Nov; 73(22):6816-27. PubMed ID: 24063893
[TBL] [Abstract][Full Text] [Related]
11. A novel reporter construct for screening small molecule inhibitors that specifically target self-renewing cancer cells.
Shanmugam G; Mohan A; Kumari K; Louis JM; Soumya Krishnan U; Balagopal PG; George NA; Sebastian P; Maliekal TT
Exp Cell Res; 2019 Oct; 383(2):111551. PubMed ID: 31401066
[TBL] [Abstract][Full Text] [Related]
12. Requirement of JNK signaling for self-renewal and tumor-initiating capacity of ovarian cancer stem cells.
Seino M; Okada M; Shibuya K; Seino S; Suzuki S; Ohta T; Kurachi H; Kitanaka C
Anticancer Res; 2014 Sep; 34(9):4723-31. PubMed ID: 25202050
[TBL] [Abstract][Full Text] [Related]
13. GSKJ4, A Selective Jumonji H3K27 Demethylase Inhibitor, Effectively Targets Ovarian Cancer Stem Cells.
Sakaki H; Okada M; Kuramoto K; Takeda H; Watarai H; Suzuki S; Seino S; Seino M; Ohta T; Nagase S; Kurachi H; Kitanaka C
Anticancer Res; 2015 Dec; 35(12):6607-14. PubMed ID: 26637876
[TBL] [Abstract][Full Text] [Related]
14. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.
Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ
J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586
[TBL] [Abstract][Full Text] [Related]
15. The cancer stem cell hypothesis: a guide to potential molecular targets.
Allegra A; Alonci A; Penna G; Innao V; Gerace D; Rotondo F; Musolino C
Cancer Invest; 2014 Nov; 32(9):470-95. PubMed ID: 25254602
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of BMK1 pathway suppresses cancer stem cells through BNIP3 and BNIP3L.
Song C; Xu Q; Jiang K; Zhou G; Yu X; Wang L; Zhu Y; Fang L; Yu Z; Lee JD; Yu SC; Yang Q
Oncotarget; 2015 Oct; 6(32):33279-89. PubMed ID: 26432836
[TBL] [Abstract][Full Text] [Related]
17. Induced cancer stem-like cells as a model for biological screening and discovery of agents targeting phenotypic traits of cancer stem cell.
Nishi M; Akutsu H; Kudoh A; Kimura H; Yamamoto N; Umezawa A; Lee SW; Ryo A
Oncotarget; 2014 Sep; 5(18):8665-80. PubMed ID: 25228591
[TBL] [Abstract][Full Text] [Related]
18. Cancer stem cells: the development of new cancer therapeutics.
Scatena R; Bottoni P; Pontoglio A; Giardina B
Expert Opin Biol Ther; 2011 Jul; 11(7):875-92. PubMed ID: 21463158
[TBL] [Abstract][Full Text] [Related]
19. Metabolic reprogramming orchestrates cancer stem cell properties in nasopharyngeal carcinoma.
Shen YA; Wang CY; Hsieh YT; Chen YJ; Wei YH
Cell Cycle; 2015; 14(1):86-98. PubMed ID: 25483072
[TBL] [Abstract][Full Text] [Related]
20. Cancer stem cells - A therapeutic target?
Maitland NJ; Collins AT
Curr Opin Mol Ther; 2010 Dec; 12(6):662-73. PubMed ID: 21154158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
